RECENT DEVELOPMENTS IN LABORATORY AND CLINICAL CANCER CHEMOTHERAPY

被引：4
|
作者：
GELLHORN, A
机构：
来源：
JOURNAL OF UROLOGY | 1953年 / 70卷 / 06期
关键词：
D O I：
10.1016/S0022-5347(17)67990-4
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：813 / 826
页数：14
相关论文
共 50 条
  • [1] RECENT DEVELOPMENTS IN CANCER-CHEMOTHERAPY
    MOSER, K
    [J]. PHARMACY INTERNATIONAL, 1981, 2 (07): : ABS1 - ABS1
  • [2] Recent developments in chemotherapy for bladder cancer
    Vaughn, DJ
    Malkowicz, SB
    [J]. ONCOLOGY-NEW YORK, 2001, 15 (06): : 763 - +
  • [3] Recent Developments of Systemic Chemotherapy for Gastric Cancer
    Arai, Hiroyuki
    Nakajima, Takako Eguchi
    [J]. CANCERS, 2020, 12 (05)
  • [4] Recent developments in chemotherapy of advanced gastric cancer
    Götze, T
    Schütte, K
    Röcken, C
    Malfertheiner, P
    Ebert, MPA
    [J]. DIGESTIVE DISEASES, 2004, 22 (04) : 360 - 365
  • [5] Recent developments in the clinical pharmacology of classical cytotoxic chemotherapy
    Boddy, AV
    [J]. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2006, 62 (01) : 27 - 34
  • [6] CHEMOTHERAPY FOR BRAIN METASTASES - RECENT DEVELOPMENTS AND CLINICAL CONSIDERATIONS
    SIEGERS, HP
    [J]. CANCER TREATMENT REVIEWS, 1990, 17 (01) : 63 - 76
  • [7] Recent developments in topoisomerase-targeted cancer chemotherapy
    Kirk E.Hevener
    Tatsiana A.Verstak
    Katie E.Lutat
    Daniel L.Riggsbee
    Jeremiah W.Mooney
    [J]. Acta Pharmaceutica Sinica B, 2018, 8 (06) : 844 - 861
  • [8] RECENT DEVELOPMENTS IN CHEMOTHERAPY
    HOWIE, JW
    [J]. LANCET, 1962, 1 (7240): : 1137 - &
  • [9] Recent developments in topoisomerase-targeted cancer chemotherapy
    Hevener, Kirk E.
    Verstak, Tatsiana A.
    Lutat, Katie E.
    Riggsbee, Daniel L.
    Mooney, Jeremiah W.
    [J]. ACTA PHARMACEUTICA SINICA B, 2018, 8 (06) : 844 - 861
  • [10] Recent developments related to the EGFR as a target for cancer chemotherapy
    Speake, G
    Holloway, B
    Costello, G
    [J]. CURRENT OPINION IN PHARMACOLOGY, 2005, 5 (04) : 343 - 349
12345